A new white paper from Advanced Medical Strategies (AMS), “2018 Specialty Drug Trends,” offers a comprehensive analysis of trends from 2018 in the specialty drug landscape.
According to the report’s key highlights, there were 59 Food and Drug Administration-approved novel drugs in 2018. The agency approved 44 specialty drugs in 2018.
Brand specialty drug spending, however, trended to the upside with a 10 percent increase between 2016-17.
But the accelerated rate of approvals has not been without its share of criticism.
“Critics have warned that issues of safety and efficacy can be overlooked in the haste of bringing new drugs to market,” the report states. “Thankfully there have been no such issues reported. So far.”
To learn more about this white paper from AMS, click here.